Inclusion Criteria:

          -  Participants in All Parts:

          -  Have Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 (ECOG 0-2 for
             Phase II)

          -  Participants with human immunodeficiency virus (HIV) infection are eligible if they
             are on effective anti-retroviral therapy with undetectable viral load within 6 months,
             provided there is no expected drug-drug interaction

          -  Participants with a history of hepatitis C virus (HCV) infection are eligible if they
             have been treated and cured

          -  Participants in Part 1:

          -  Are participants with advanced solid tumors, except for advanced prostate cancer, for
             whom no standard of care therapy exists, or in whom conventional therapy is not
             reliably effective, or in whom treatment with study intervention can be reasonably
             expected to provide clinical benefit

          -  Participants in Part 2:

          -  Are participants with advanced Germline Breast Cancer Gene (BRCA)1/2-Mutant Wild Type
             (gBRCA1/2)-mutant, Poly(ADP-Ribose) Polymerase Inhibitor(s) (PARPi)-resistant Human
             Epidermal Growth Factor Receptor 2 Negative (HER2)- breast cancer. There is no limit
             for prior lines of chemotherapy for metastatic disease

          -  Participants with at least one measurable lesion that is suitable for repeated
             assessment as per RECIST 1.1

          -  Participants in Part 3:

          -  Are participants with advanced BRCA1/2 wild-type, Homologous Recombination Repair Gene
             Mutated (HRRm) Human Epidermal Growth Factor Receptor 2 Negative (HER2)- breast cancer

          -  Participants must not have had prior treatment with a PARPi in any disease setting

          -  All participants with at least one measurable or non-measurable but evaluable lesion
             that is suitable for repeated assessment as per RECIST 1.1

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Participants with clinically relevant (that is [i.e], active), uncontrolled
             intercurrent illness including, but not limited to, severe active infection (i.e.
             requiring hospitalization and/or intravenous antibiotics), uncontrolled arterial
             hypertension, i.e. systolic blood pressure (BP) > 140 millimeter of mercury (mmHg),
             diastolic BP > 90 mmHg, symptomatic congestive heart failure (>= New York Heart
             Association Classification Class II), unstable angina pectoris or myocardial
             infarction, cardiac arrhythmia requiring medication, cerebral vascular
             accident/stroke, or any psychiatric illness/social situations that would limit
             compliance with study requirements

          -  Participants with a known additional malignancy that is progressing and/or requires
             active treatment. In addition, participants must not have a known history or current
             diagnosis of Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) at any
             time or have been diagnosed with another malignancy within 3 years of starting
             treatment. Exceptions include fully resected basal cell carcinoma of the skin or
             squamous cell carcinoma of the skin, in situ cervical cancer, fully resected ductal
             carcinoma in situ, and Stage IA, Grade I endometrioid endometrial cancer with no
             myometrial invasion, that has undergone curative therapy

          -  Participants diagnosed with hereditary diseases characterized by genetic defects of
             Deoxyribonucleic acid (DNA) repair mechanisms, including ataxia telangiectasia,
             Nijmegen breakage syndrome, Werner syndrome, Bloom Syndrome, Fanconi anemia, xeroderma
             pigmentosum, Cockayne syndrome, and trichothiodystrophy

          -  Treatment with live or live attenuated vaccine within 30 days of dosing

          -  Participants with clinically relevant, uncontrolled intercurrent illness, unstable
             brain metastases, has a known additional malignancy that is progressing and/or
             requires active treatment

          -  Received hematopoietic growth factor (example, granulocyte colony-stimulating factor,
             erythropoietin) within 14 days prior to the first dose of study intervention

          -  Participants receiving treatment with proton-pump inhibitors that cannot be
             discontinued at least 1 week before first dose of study intervention and for the
             duration of the study

          -  Other protocol defined inclusion criteria could apply